-
1
-
-
84877596833
-
The 1000 Genomes Project Consortium An integrated map of genetic variation from 1092 human genomes
-
Abecasis GR, Auton A, Brooks LD, et al., The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1092 human genomes. Nature 2012; 491:56-65.
-
(2012)
Nature
, vol.491
, pp. 56-65
-
-
Abecasis, G.R.1
Auton, A.2
Brooks, L.D.3
-
5
-
-
75549084134
-
Personalized genomic information: Preparing for the future of genetic medicine
-
Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat Rev Genet 2010; 11:161-165.
-
(2010)
Nat Rev Genet
, vol.11
, pp. 161-165
-
-
Guttmacher, A.E.1
McGuire, A.L.2
Ponder, B.3
Stefansson, K.4
-
6
-
-
84891820778
-
Coronary artery disease risk loci identified in over 190 000 individuals implicate lipid metabolism and inflammation as key causal pathways
-
The CARDIoGRAMplusC4D Consortium
-
The CARDIoGRAMplusC4D Consortium. Coronary artery disease risk loci identified in over 190 000 individuals implicate lipid metabolism and inflammation as key causal pathways. Nat Genet 2013; 45:25-33.
-
(2013)
Nat Genet
, vol.45
, pp. 25-33
-
-
-
7
-
-
84899474573
-
On Behalf of the NHLBIGO Exome Sequencing Project Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset
-
Accessed on March 5 2014 Epub ahead of print
-
Gordon AS, Tabor HK, Johnson AD, et al.,On Behalf of the NHLBIGO Exome Sequencing Project. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset [Accessed on March 5, 2014]. Hum Mol Genet 2013. [Epub ahead of print]
-
(2013)
Hum Mol Genet
-
-
Gordon, A.S.1
Tabor, H.K.2
Johnson, A.D.3
-
8
-
-
0028041629
-
Economic impact of heart failure in the United States: Time for a different approach
-
O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13:S107-S112.
-
(1994)
J Heart Lung Transplant
, vol.13
-
-
O'Connell, J.B.1
Bristow, M.R.2
-
9
-
-
84899491296
-
Dilated cardiomyopathies
-
Fuster V, Walsh RA, Harrington RA, editors 13th ed. New York: The McGraw-Hill Companies, Inc Chapter 32
-
Mestroni LJ, Gilbert EM, Lowes BL, Bristow RM. Dilated cardiomyopathies. In: Fuster V, Walsh RA, Harrington RA, editors. Hurst's the heart, 13th ed. New York: The McGraw-Hill Companies, Inc; 2011. pp. 821-836. Chapter 32.
-
(2011)
Hurst's the Heart
, pp. 821-836
-
-
Mestroni, L.J.1
Gilbert, E.M.2
Lowes, B.L.3
Bristow, R.M.4
-
10
-
-
84857363880
-
Pharmacogenetic targeting of drugs for heart failure
-
Bristow MR. Pharmacogenetic targeting of drugs for heart failure. Pharmacol Ther 2012; 134:107-115.
-
(2012)
Pharmacol Ther
, vol.134
, pp. 107-115
-
-
Bristow, M.R.1
-
11
-
-
58149267604
-
Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure
-
Taylor MR, Slavov D, Humphrey K, et al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 2009; 19:35-43.
-
(2009)
Pharmacogenet Genomics
, vol.19
, pp. 35-43
-
-
Taylor, M.R.1
Slavov, D.2
Humphrey, K.3
-
12
-
-
0037057235
-
Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure
-
Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1-and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-1142.
-
(2002)
N Engl J Med
, vol.347
, pp. 1135-1142
-
-
Small, K.M.1
Wagoner, L.E.2
Levin, A.M.3
-
13
-
-
33745902221
-
Association of parental heart failure with risk of heart failure in offspring
-
Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006; 355:138-147.
-
(2006)
N Engl J Med
, vol.355
, pp. 138-147
-
-
Lee, D.S.1
Pencina, M.J.2
Benjamin, E.J.3
-
14
-
-
77955868822
-
Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: A prospective meta-analysis from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium
-
Smith NL, Felix JF, Morrison AC, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010; 3:256-266.
-
(2010)
Circ Cardiovasc Genet
, vol.3
, pp. 256-266
-
-
Smith, N.L.1
Felix, J.F.2
Morrison, A.C.3
-
15
-
-
77955909864
-
Genomic variation associated with mortality among adults of European and African ancestry with heart failure: The cohorts for heart and aging research in genomic epidemiology consortium
-
Morrison AC, Felix JF, Cupples LA, et al. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet 2010; 3:248-255.
-
(2010)
Circ Cardiovasc Genet
, vol.3
, pp. 248-255
-
-
Morrison, A.C.1
Felix, J.F.2
Cupples, L.A.3
-
16
-
-
41749117082
-
Emerging role of pharmacogenomics in heart failure
-
McNamara DM. Emerging role of pharmacogenomics in heart failure. Curr Opin Cardiol 2008; 23:261-268.
-
(2008)
Curr Opin Cardiol
, vol.23
, pp. 261-268
-
-
McNamara, D.M.1
-
17
-
-
79958085599
-
Cardiovascular pharmacogenomics and individualized drug therapy
-
Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol 2009; 6:632-638.
-
(2009)
Nat Rev Cardiol
, vol.6
, pp. 632-638
-
-
Pereira, N.L.1
Weinshilboum, R.M.2
-
18
-
-
34247593030
-
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure
-
Lobmeyer MT, Gong Y, Terra SG, et al. Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics 2007; 17:277-282.
-
(2007)
Pharmacogenet Genomics
, vol.17
, pp. 277-282
-
-
Lobmeyer, M.T.1
Gong, Y.2
Terra, S.G.3
-
19
-
-
76549133595
-
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure
-
Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3:21-28.
-
(2010)
Circ Heart Fail
, vol.3
, pp. 21-28
-
-
Bristow, M.R.1
Murphy, G.A.2
Krause-Steinrauf, H.3
-
20
-
-
0032836517
-
Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials
-
Carson P, Ziesche S, Johnson G, Cohn JN, Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999; 5:178-187.
-
(1999)
J Card Fail
, vol.5
, pp. 178-187
-
-
Carson, P.1
Ziesche, S.2
Johnson, G.3
Cohn, J.N.4
-
21
-
-
33748079774
-
Better identification of patients who benefit from implantable cardioverter defibrillators by genotyping the G-protein beta3 subunit (GNB3) c825t polymorphism
-
Wieneke H, Naber CN, Piaszek L, et al. Better identification of patients who benefit from implantable cardioverter defibrillators by genotyping the G-protein beta3 subunit (GNB3) c825t polymorphism. Basic Res Cardiol 2006; 101:447-451.
-
(2006)
Basic Res Cardiol
, vol.101
, pp. 447-451
-
-
Wieneke, H.1
Naber, C.N.2
Piaszek, L.3
-
22
-
-
84856164890
-
A systematic review on pharmacogenetics in cardiovascular disease: Is it ready for clinical application?
-
Verschuren JJ, Trompet S, Wessels JA, et al. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Eur Heart J 2012; 33:165-175.
-
(2012)
Eur Heart J
, vol.33
, pp. 165-175
-
-
Verschuren, J.J.1
Trompet, S.2
Wessels, J.A.3
-
23
-
-
84863631944
-
Genetics and cardiovascular disease: A policy statement from the American Heart Association
-
Ashley EA, Hershberger RE, Caleshu C, et al. Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation 2012; 126:142-157.
-
(2012)
Circulation
, vol.126
, pp. 142-157
-
-
Ashley, E.A.1
Hershberger, R.E.2
Caleshu, C.3
-
24
-
-
80052969185
-
Pharmacogenomics: Application to the management of cardiovascular disease
-
Johnson JA, Cavallari LH, Beitelshees AL, et al. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther 2011; 90:519-531.
-
(2011)
Clin Pharmacol Ther
, vol.90
, pp. 519-531
-
-
Johnson, J.A.1
Cavallari, L.H.2
Beitelshees, A.L.3
-
25
-
-
84890988743
-
Genetics and genomics for the prevention and treatment of cardiovascular disease: Update A scientific statement from the American Heart Association
-
Ganesh SK, Arnett DK, Assimes TL, et al. Genetics and genomics for the prevention and treatment of cardiovascular disease: update. A scientific statement from the American Heart Association. Circulation 2013; 128:2813-2851.
-
(2013)
Circulation
, vol.128
, pp. 2813-2851
-
-
Ganesh, S.K.1
Arnett, D.K.2
Assimes, T.L.3
-
26
-
-
84889873119
-
EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin
-
Pirmohamed M, Burnside G, Eriksson N, et al., EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369:2294-2303.
-
(2013)
N Engl J Med
, vol.369
, pp. 2294-2303
-
-
Pirmohamed, M.1
Burnside, G.2
Eriksson, N.3
-
27
-
-
84889824971
-
COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing
-
Kimmel SE, French B, Kasner SE, et al., COAG Investigators. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369:2283-2293.
-
(2013)
N Engl J Med
, vol.369
, pp. 2283-2293
-
-
Kimmel, S.E.1
French, B.2
Kasner, S.E.3
-
28
-
-
84876998756
-
Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: A review of ticagrelor
-
Davis EM, Knezevich JT, Teply RM. Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor. Clin Pharmacol 2013; 5:67-83.
-
(2013)
Clin Pharmacol
, vol.5
, pp. 67-83
-
-
Davis, E.M.1
Knezevich, J.T.2
Teply, R.M.3
-
29
-
-
17444439098
-
Polymorphisms of the beta( 2)-adrenergic receptor determine exercise capacity in patients with heart failure
-
Wagoner LE, Craft LL, Singh B, et al. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86:834-840.
-
(2000)
Circ Res
, vol.86
, pp. 834-840
-
-
Wagoner, L.E.1
Craft, L.L.2
Singh, B.3
-
30
-
-
84881148332
-
Biomarker-guided therapies in heart failure: A forum for unified strategies
-
Fiuzat M, O'Connor CM, Gueyffier F, et al. Biomarker-guided therapies in heart failure: a forum for unified strategies. J Card Fail 2013; 19:592-599.
-
(2013)
J Card Fail
, vol.19
, pp. 592-599
-
-
Fiuzat, M.1
O'Connor, C.M.2
Gueyffier, F.3
|